This study is about teenagers and adults with hereditary angioedema (HAE) type I and type II. In this study, the burden of illness means the impact of HAE in terms of long-term health outcomes and the financial cost. The main aims of this study are as follows: * to learn how often, how severe and where on the body HAE attacks occur. * to describe how HAE prophylaxis and on-demand medicines are prescribed and used. (Prophylaxis medicines prevent a bleed from happening and on-demand medicines treat a bleed when it occurs.) This study is about collecting data only; participants will not receive treatment as part of this study. Existing data available in the participant's medical records will be collected. Participants will be asked to complete an electronic questionnaire either on a website or by using an app on their mobile phone; data from this questionnaire will also be collected. Participants do not need to visit their doctor in addition to their normal visits.
Age range
12 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Number of Participants With HAE Attacks Occurrence During Study Period
Timeframe: Throughout the study period (up to 6 months)
Number of Participants Categorized Based on Characteristics of HAE Attacks During Study Period
Timeframe: Throughout the study period (up to 6 months)
Time Interval Between HAE Attacks During Study Period
Timeframe: Throughout the study period (up to 6 months)
Duration of Each HAE Attacks During Study Period
Timeframe: Throughout the study period (up to 6 months)
Number of Participants Based on Type of HAE Prophylactic Treatments
Timeframe: Throughout the study period (up to 6 months)
Number of Participants Based on Long-term or Short-term HAE Prophylactic Treatment
Timeframe: Throughout the study period (up to 6 months)
Number of Participants Categorized Based on Reasons for HAE Prophylactic Treatment Initiation
Timeframe: Throughout the study period (up to 6 months)
Duration of HAE Prophylactic Treatment
Timeframe: Throughout the study period (up to 6 months)
Number of Participants Categorized Based on Dose and Route of Administration for HAE Prophylactic Treatment
Timeframe: Throughout the study period (up to 6 months)
Number of Participants Categorized Based on Reasons for HAE Prophylactic Treatment Discontinuation
Timeframe: Throughout the study period (up to 6 months)
Number of Participants Based on Type of HAE On-demand Treatment
Timeframe: Throughout the study period (up to 6 months)
Duration of HAE On-demand Treatment
Timeframe: Throughout the study period (up to 6 months)
Number of Participants Categorized Based on Dose and Route of Administration for HAE On-demand Treatment
Timeframe: Throughout the study period (up to 6 months)
Number of Participants Associated Between Prescriptions Patterns and HAE Attacks
Timeframe: Throughout the study period (up to 6 months)